Fig. 2.
The CFU-GM yield of different mobilization protocols used in the authors' institution. ‘3-4gm Cy’ denotes patients who received cyclophosphamide 3 to 4 g/m2 intravenously and had blood cells harvested during recovery from myelosuppression. ‘7gm Cy’ denotes patients who received cyclophosphamide 7 g/m2 intravenously and had blood cells harvested during recovery from myelosuppression. ‘G-CSF, pretreated’ denotes patients who received G-CSF at 12 μg/kg subcutaneously and had blood cells harvested on days 5, 6, and 7. ‘Chemo + G-CSF’ and ‘Chemo + GM-CSF’ denote patients who received myelosuppressive chemotherapy and G-CSF or GM-CSF and had blood cells harvested during recovery from myelosuppression. ‘G-CSF, de novo’ denotes chemotherapy naive patients who received G-CSF at 12 μg/kg subcutaneously daily and had blood cells harvested on days 5, 6, and 7. ‘G-CSF + SCF’ denotes chemotherapy naive patient who received G-CSF at 12 μg/kg subcutaneously daily and SCF at 5 to 15 μg/kg subcutaneously daily and had blood cells harvested on days 5, 6, and 7 of G-CSF administration. For each group of patients the horizontal bar denotes the median value, the box plot denotes the 5th and the 95th percentiles, and the whiskers denote the maximum and minimum values.